{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:15:58Z","timestamp":1791814558751,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Sinonasal tumors consist of a group of rare heterogeneous malignancies, accounting for 3%\u20135% of all head and neck cancers. Although squamous cell carcinomas make up a significant portion of cancers arising in the sinonasal tract, there are a variety of aggressive tumor types that can present with a poorly differentiated morphology and continue to pose diagnostic challenges. Accurate classification of these unique malignancies has treatment implications for patients. Recent discoveries have allowed more detailed molecular characterization of subsets of these tumor types, and may lead to individualized treatments. INI-1 (SMARCB1)\u2013deficient sinonasal carcinoma is a recently identified subtype of sinonasal malignancy, which is characterized by deletion of the INI-1 tumor suppressor gene. Loss of INI-1 expression has emerged as an important diagnostic feature in several human malignancies including a subset of sinonasal carcinomas. In this article, we present a case of INI-1 (SMARCB1)\u2013deficient sinonasal carcinoma, provide an overview of recent advances in histological and molecular classification of sinonasal malignancies, and discuss challenges of caring for patients with these rare malignancies, as well as potential treatment implications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>Clinicians and pathologists should recognize that a variety of sinonasal tumors can present with a poorly differentiated morphology that warrants further workup and molecular classification. Routine workup of poorly or undifferentiated sinonasal tumors should include testing for INI-1\/SMARCB1, SMARCA4, and NUT. Patients with these molecularly defined subsets of tumors may benefit from clinical trials that seek to exploit these molecular alterations. The EZH2 inhibitor, tazemetostat, has demonstrated some antitumor activity in INI-1\u2013deficient tumors, and is currently under investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0830","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T04:04:07Z","timestamp":1587960247000},"page":"738-744","source":"Crossref","is-referenced-by-count":22,"title":["INI-1 (SMARCB1)\u2013Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies"],"prefix":"10.1093","volume":"25","author":[{"given":"Khvaramze","family":"Shaverdashvili","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Azimi-Nekoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Akbar","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology - Head and Neck Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Ow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"},{"name":"Department of Otorhinolaryngology - Head and Neck Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Castellucci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"2021122510522690800_onco13335-bib-0001","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hed.23606","article-title":"Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: A retrospective review","volume":"37","author":"Gray","year":"2015","journal-title":"Head Neck"},{"key":"2021122510522690800_onco13335-bib-0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12105-017-0791-4","article-title":"Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the nasal cavity, paranasal sinuses and skull base","volume":"11","author":"Stelow","year":"2017","journal-title":"Head Neck Pathol"},{"key":"2021122510522690800_onco13335-bib-0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12105-017-0796-z","article-title":"Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What is new in the 2017 WHO Blue Book for Tumors and Tumor-Like Lesions of the Neck and Lymph Nodes","volume":"11","author":"Katabi","year":"2017","journal-title":"Head Neck Pathol"},{"key":"2021122510522690800_onco13335-bib-0004","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-15-0340","article-title":"High-frequency targetable EGFR mutations in sinonasal squamous cell carcinomas arising from inverted sinonasal papilloma","volume":"75","author":"Udager","year":"2015","journal-title":"Cancer Res"},{"key":"2021122510522690800_onco13335-bib-0005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/annonc\/mdx736","article-title":"Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillmoas and associated sinonasal squamous cell carcinomas","volume":"29","author":"Udager","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122510522690800_onco13335-bib-0006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/PAS.0b013e3181882c54","article-title":"Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma","volume":"33","author":"Hornick","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2021122510522690800_onco13335-bib-0007","first-page":"323","article-title":"The role of INI1 and the SWI\/SNF complex in the development of rhabdoid tumors: Meeting summary from the workshop on childhood atypical teratoid\/rhabdoid tumors","volume":"62","author":"Biegel","year":"2002","journal-title":"Cancer Res"},{"key":"2021122510522690800_onco13335-bib-0008","first-page":"74","article-title":"Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors","volume":"59","author":"Biegel","year":"1999","journal-title":"Cancer Res"},{"key":"2021122510522690800_onco13335-bib-0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3171\/jns.1996.85.1.0056","article-title":"Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood: Definition of an entity","volume":"85","author":"Rorke","year":"1996","journal-title":"J Neurosurg"},{"key":"2021122510522690800_onco13335-bib-0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJM198909283211317","article-title":"Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain","volume":"321","author":"Biegel","year":"1989","journal-title":"New Engl J Med"},{"key":"2021122510522690800_onco13335-bib-0011","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/gcc.22159","article-title":"Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material","volume":"53","author":"Le Loarer","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122510522690800_onco13335-bib-0012","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/modpathol.2008.44","article-title":"Renal medullary carcinoma: Rhabdoid features and the absence of INI1 expression as markers of aggressive behavior","volume":"21","author":"Cheng","year":"2008","journal-title":"Mod Pathol"},{"key":"2021122510522690800_onco13335-bib-0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/PAS.0b013e31805f6775","article-title":"Myoepithelial carcinoma of soft tissue in children: An aggressive neoplasm analyzed in a series of 29 cases","volume":"31","author":"Gleason","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2021122510522690800_onco13335-bib-0014","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e318161781a","article-title":"SMARCB1\/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: A special reference to SMARCB1\/INI1 negative variant extraskeletal myxoid chondrosarcoma","volume":"32","author":"Kohashi","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"2021122510522690800_onco13335-bib-0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pathol-012414-040445","article-title":"SWI\/SNF chromatin remodeling and human malignancies","volume":"10","author":"Masliah-Planchon","year":"2015","journal-title":"Ann Rev Pathol"},{"key":"2021122510522690800_onco13335-bib-0016","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.eururo.2015.09.027","article-title":"Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas","volume":"69","author":"Calderaro","year":"2016","journal-title":"Eur Urol"},{"key":"2021122510522690800_onco13335-bib-0017","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cas.13173","article-title":"Oncogenic roles of SMARCB1\/INI1 and its deficient tumors","volume":"108","author":"Kohashi","year":"2017","journal-title":"Cancer Sci"},{"key":"2021122510522690800_onco13335-bib-0018","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12105-016-0752-3","article-title":"INI1 (SMARCB1)-deficient sinonasal carcinoma: A clinicopathologic report of 2 cases","volume":"11","author":"Wasserman","year":"2017","journal-title":"Head Neck Pathol"},{"key":"2021122510522690800_onco13335-bib-0019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/PAS.0000000000000797","article-title":"SMARCB1 (INI-1)-deficient sinonasal carcinoma: A series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity","volume":"41","author":"Agaimy","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"2021122510522690800_onco13335-bib-0020","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1038\/sj.onc.1205841","article-title":"A key role of the hSNF5\/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle","volume":"21","author":"Versteege","year":"2002","journal-title":"Oncogene"},{"key":"2021122510522690800_onco13335-bib-0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/labinvest.2015.144","article-title":"The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: Implications in targeted cancer therapies","volume":"96","author":"Yang","year":"2016","journal-title":"Lab Invest"},{"key":"2021122510522690800_onco13335-bib-0022","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2013.37","article-title":"Activation of beta-catenin\/TCF targets following loss of the tumor suppressor SNF5","volume":"33","author":"Mora-Blanco","year":"2014","journal-title":"Oncogene"},{"key":"2021122510522690800_onco13335-bib-0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122510522690800_onco13335-bib-0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1139\/O08-113","article-title":"The role of INI1\/hSNF5 in gene regulation and cancer","volume":"87","author":"Stojanova","year":"2009","journal-title":"Biochem Cell Biol"},{"key":"2021122510522690800_onco13335-bib-0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2016.03.013","article-title":"Emerging roles for Polycomb proteins in cancer","volume":"36","author":"Pasini","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"2021122510522690800_onco13335-bib-0026","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122510522690800_onco13335-bib-0027","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"(2014) Regulation and Role of EZH2 in Cancer","volume":"46","author":"Yamaguchi","year":"2014","journal-title":"Cancer Res Treat"},{"key":"2021122510522690800_onco13335-bib-0028","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2016-06-723916","article-title":"EZH2: A pleiotropic protein","volume":"128","author":"Burmeister","year":"2016","journal-title":"Blood"},{"key":"2021122510522690800_onco13335-bib-0029","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/9\/738\/41920840\/oncolo_25_9_738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/9\/738\/41920840\/oncolo_25_9_738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:53:05Z","timestamp":1640429585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/9\/738\/6443896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,12]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0830","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,6,12]]}}}